Goldman Sachs’s Insys Therapeutics, Inc. INSY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-157,592
Closed -$728K 5501
2019
Q1
$728K Buy
157,592
+10,688
+7% +$50.6K ﹤0.01% 4232
2018
Q4
$514K Sell
146,904
-722
-0.5% -$5.02K ﹤0.01% 4347
2018
Q3
$1.49M Buy
147,626
+3,432
+2% +$27.4K ﹤0.01% 3791
2018
Q2
$1.04M Buy
144,194
+27,241
+23% +$190K ﹤0.01% 4040
2018
Q1
$706K Sell
116,953
-723
-0.6% -$5.97K ﹤0.01% 4270
2017
Q4
$1.13M Sell
117,676
-16,163
-12% -$106K ﹤0.01% 4239
2017
Q3
$1.19M Sell
133,839
-3,614
-3% -$37.3K ﹤0.01% 4431
2017
Q2
$1.74M Sell
137,453
-89,115
-39% -$1.05M ﹤0.01% 3950
2017
Q1
$2.38M Sell
226,568
-39,168
-15% -$417K ﹤0.01% 3573
2016
Q4
$2.44M Buy
265,736
+78,476
+42% +$887K ﹤0.01% 3669
2016
Q3
$2.21M Sell
187,260
-466,877
-71% -$7.1M ﹤0.01% 3745
2016
Q2
$8.46M Buy
654,137
+408,606
+166% +$5.96M ﹤0.01% 2443
2016
Q1
$3.93M Sell
245,531
-119,503
-33% -$2.27M ﹤0.01% 2901
2015
Q4
$10.5M Sell
365,034
-349,812
-49% -$9.69M ﹤0.01% 2217
2015
Q3
$20.3M Buy
714,846
+644,557
+917% +$23.7M 0.01% 1699
2015
Q2
$2.52M Buy
70,289
+33,893
+93% +$1.06M ﹤0.01% 3607
2015
Q1
$1.06M Sell
36,396
-91,186
-71% -$2.41M ﹤0.01% 4411
2014
Q4
$2.69M Sell
127,582
-212,144
-62% -$4.19M ﹤0.01% 3549
2014
Q3
$6.59M Buy
339,726
+62,864
+23% +$987K ﹤0.01% 2746
2014
Q2
$4.32M Buy
276,862
+197,980
+251% +$3.2M ﹤0.01% 3209
2014
Q1
$1.63M Sell
78,882
-456
-0.6% -$9.04K ﹤0.01% 4157
2013
Q4
$1.02M Buy
+79,338
New +$1.1M ﹤0.01% 4729

Other funds holding INSY

Goldman Sachs's INSY Position: Q2 2019 in Review

Goldman Sachs sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 157,592 shares — an estimated $728K sold.

Goldman Sachs first reported a position in INSY in Q4 2013 and held it in 22 quarters. The position peaked at $20.3M in Q3 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Goldman Sachs reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Goldman Sachs sold 157,592 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $728K.
  • Goldman Sachs first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 22 quarters.
  • Goldman Sachs's Insys Therapeutics, Inc. position peaked at $20.3M in Q3 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Goldman Sachs's 13F filing for Q2 2019, filed 14 Aug 2019.